Qureight
Summary active Updated Aug 30, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Qureight is a Cambridge, UK-based healthcare technology company that develops AI-powered medical imaging solutions to accelerate clinical trials for lung and heart diseases, offering an end-to-end platform for managing, analysing, and interpreting imaging data to generate precise trial endpoints 123. On 2026-07-29, Qureight closed a $20 million Series B financing led by Molten Ventures, with participation from Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension 123. The company will use the capital to build an AI imaging laboratory housing its 3D chest imaging foundation model and expand into asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity 12. Dr Inga Deakin (Molten Ventures) and Anna Salim (Hargreave Hale) joined the board 2.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-29 | Series B | $20M | Molten Ventures | Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, Ascension 123 |
What Investors Say
What Founders Say
Sources
-
Tech.eu, “Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials,” July 29, 2026. Accessed August 2026. https://tech.eu/2026/07/29/qureight-secures-20m-series-b-to-expand-ai-powered-imaging-platform-for-clinical-trials/↩↩↩↩
-
Qureight press release, “Qureight closes $20 million Series B financing,” July 29, 2026. Accessed August 2026. https://www.qureight.com/news/qureight-closes-20-million-series-b-financing↩↩↩↩↩
-
Drug Discovery World, “Qureight closes $20 million Series B financing,” July 2026. Accessed August 2026. https://www.ddw-online.com/qureight-closes-20-million-series-b-financing-43176-202607/↩↩↩